



1648 \$

Dkt. 2048/57906-B/JPW/MAF/DJK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : William Olson and Paul Maddon

Serial No. : 09/594,983

Examiner: Shannon A. Foley

Filed : June 15, 2000

Group Art Unit: 1648

For : SYNERGISTIC INHIBITION OF HIV-1 FUSION AND
ATTACHMENT, COMPOSITIONS AND ANTIBODIES THERETO

1185 Avenue of the Americas
New York, NY 10036
September 3, 2003

RECEIVED

SEP 11 2003

TECH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In compliance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references, which are listed on the accompanying form PTO-1449 (**Exhibit A**).

1. Co, et al., "Humanized Antibodies for Antiviral Therapy", Proceedings of the National Academy of Science, USA, April 1991, Vol. 88, pages 2869-2873.
2. Trkola, et al., "Potent Broad-spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140", Journal of Virology, January 2001, Vol. 75, No. 2, pages 579-588.
3. Olson, et al., "Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, Gp 120 binding and CC-chemokine Activity of Monoclonal Antibodies to

09/09/2003 FFAWAEIA 00000104 09594983

01 FC:1006

180.00 OP

- CCR5", Journal of Virology, May 1999, Vol. 73, No. 5, pages 4145-4155.
4. Parren, et al., "Antibody Protects Macaques Against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro", Journal of Virology, Vol. 75, No. 17, pages 8340-8347.
 5. Lehner, et al., "Immunogenicity of the Extracellular Domains of C-C Chemokine Receptor 5 and the In Vitro Effects on Simian Immunodeficiency or HIV Infectivity", Journal of Immunology, January 2001, Vol. 166, No. 12, pages 7446-7455.
 6. Wu, et al., "CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophagetropic HIV-1 in Vitro", Journal of Experimental Medicine, May 5, 1997, Vol. 185, No. 9, pages 1681-1691.

The subject application is a continuation-in-part of and claims benefit under 35 U.S.C. § 120 of U.S. Serial No. 09/464,902, filed December 16, 1999. Copies of references 1-6 listed above were submitted to the United States Patent and Trademark Office in a Supplemental Information Disclosure Statement on September 3, 2003 in connection with U.S. Serial No. 09/464,902. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

None of the above references are believed to teach or suggest the presently claimed invention, whether taken alone or in combination with any other cited reference(s).

Applicants: William Olson and Paul Maddon
Serial No.: 09/594,983
Filed: June 15, 2000
Page 3

The undersigned hereby certifies, under 37 C.F.R. 1.98 (e)(1), that each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counter part foreign application not more than three months prior to the filing of the information disclosure statement. Specifically, items 1-6 were cited in the International Search Report, dated August 13, 2003 (**Exhibit B**), received in International Application No. PCT/US3/05500. The Search Report additionally includes U.S. Patent 6,528,625 B1 to Wu, et al. This reference has previously been cited by the applicants in the Supplementary Information Disclosure Statement included with their Amendment In Response to December 3, 2002 Final Office Action filed June 5, 2003.

The Examiner is respectfully requested to make the references cited above of record in the present case by initialing and dating a copy of the form PTO-1449 attached hereto as Exhibit A and returning it to applicants' representative with the next communication concerning this application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Applicants: William Olson and Paul Maddon
Serial No.: 09/594,983
Filed: June 15, 2000
Page 4

A fee of \$180.00 is believed due under 37 C.F.R. §1.97(d)(2) for submission of this Supplemental Information Disclosure Statement and a check for the subject amount is included herewith. If any additional fee is required, authorization is herewith provided to charge the fee concerning this matter to Deposit Account No. 03-3125.

Respectfully submitted,

Mark A. Farley

John P. White
Registration No. 28,678
Mark A. Farley
Registration No. 33,170
Attorneys for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:	
Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450	
<i>Mark A. Farley</i>	<i>9/3/03</i>
John P. White	Date
Reg. No. 28,678	
Mark A. Farley	
Reg. No. 33,170	



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 2048/57906-B /JPW/MAF/DJK		Serial No. 09/594,983		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant(s) William C. Olson et al.				
				Filing Date June 15, 2000		Art Unit 1648		
U.S. PATENT DOCUMENTS								
Examiner Initials		Document Number		Date	Name	Class	Subclass	Filing Date If Appropriate
								RECEIVED SEP 11 2003 TECH CENTER 1600/2900
FOREIGN PATENT DOCUMENTS								
		Document Number		Date	Country	Class	Subclass	Translation
								Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Co, et al., "Humanized Antibodies for Antiviral Therapy", Proceedings of the National Academy of Science, USA, April 1991, Vol. 88, pages 2869-2873.						
		Trkola, et al., "Potent Broad-spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140", Journal of Virology, January 2001, Vol. 75, No. 2, pages 579-588.						
		Olson, et al., "Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, Gp 120 binding and CC-chemokine Activity of Monoclonal Antibodies to CCR5", Journal of Virology, May 1999, Vol. 73, No. 5, pages 4145-4155.						
		Parren, et al., "Antibody Protects Macaques Against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro", Journal of Virology, Vol. 75, No. 17, pages 8340-8347						
		Lehner, et al., "Immunogenicity of the Extracellular Domains of C-C Chemokine Receptor 5 and the In Vitro Effects on Simian Immunodeficiency or HIV Infectivity", Journal of Immunology, January 2001, Vol. 166, No. 12, pages 7446-7455						
		Wu, et al., "CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophagetropic HIV-1 in Vitro", Journal of Experimental Medicine, May 5, 1997, Vol. 185, No. 9, pages 1681-1691.						
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								